LIL-HM4B3-100μg / 询价
LIL-HM4B3-500μg / 询价
LIL-HM4B3-500μgx2 / 询价
- 客服电话
- 技术支持
Human LILRB3/CD85a/ILT5 Protein
Recombinant Human LILRB3/CD85a/ILT5 Protein is expressed from HEK293 with His tag and Avi tag at the C-Terminus. It contains Gly24-Glu443.[Accession | O75022-1]
The protein has a predicted MW of 50 kDa. Due to glycosylation, the protein migrates to 60-72 kDa based on Tris-Bis PAGE result.
Less than 1EU per μg by the LAL method.
> 95% as determined by Tris-Bis PAGE
> 95% as determined by HPLC
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
-20 to -80°C for 12 months as supplied from date of receipt.
-80°C for 3-6 months after reconstitution.
2-8°C for 2-7 days after reconstitution.
Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Human LILRB3 on Tris-Bis PAGE under reduced condition. The purity is greater than 95%.
The purity of Human LILRB3 is greater than 95% as determined by SEC-HPLC.
Immobilized Human LILRB3, His Tag at 5μg/ml (100μl/well) on the plate. Dose response curve for Anti-LILRB3 Antibody, hFc Tag with the EC50 of 12.5ng/ml determined by ELISA.
Leukocyte immunoglobulin-like receptor subfamily B (LILRB3), also known as ILT5, LIR3, and CD85a, is an immunoglobulin superfamily member that is involved in immune regulation. Subfamily B members have cytoplasmic immunoreceptor tyrosine-based inhibitory motifs (ITIMs) that inhibit signaling events via phosphatase SHP-1.LILRB3 may act as receptor for class I MHC antigens. Becomes activated upon coligation of LILRB3 and immune receptors, such as FCGR2B and the B-cell receptor.
CD85a; ILT5; ILT-5; LILRB3; LIR3; LIR3CD85A; LIR-3MGC138403; PIRB; HL9
(1)Huang J , Burke P S , Cung T D H , et al. Leukocyte Immunoglobulin-Like Receptors Maintain Unique Antigen-Presenting Properties of Circulating Myeloid Dendritic Cells in HIV-1-Infected Elite Controllers[J]. Journal of Virology, 2010, 84(18):9463-9471.
